세계의 듀센형 근이영양증 치료제 시장 - 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Duchenne Muscular Dystrophy Drugs Market size is projected to expand at an 11.6% CAGR from 2024 to 2032, led by the rising government and regulatory support along with increasing R and D efforts. Governments are expediting the availability of new treatments for duchenne muscular dystrophy (DMD) through funding and regulatory approvals. Researchers are innovating therapies and enhancing existing drugs to meet the needs of DMD patients. For instance, in March 2024, the U.S. FDA nodded Duvyzat (givinostat), an oral treatment for DMD, for patients aged six years and older.

The overall market is segregated into drug type, route of administration, and region.

Based on drug type, the DMD drugs market value from the gene therapy segment is estimated to grow at a significant rate from 2024 to 2032, driven by the urgent need to tackle the condition's genetic root. Gene therapies aim to correct or replace the faulty dystrophin gene, pivotal in muscle degeneration. Researchers are directly delivering functional dystrophin gene copies to muscle cells, employing advanced vectors for optimal gene transfer and expression.

Duchenne muscular dystrophy drugs industry from the injectable route of administration segment is anticipated to grow at a substantial CAGR through 2032 fueled by the rising demand for effective treatment delivery. Injectables offer direct access to muscle tissue or systemic circulation, enhancing drug absorption and efficacy. Moreover, advancements in injectable technologies are paving the way for efficient delivery systems, including sustained-release formulations and novel delivery methods.

Regionally, the Asia Pacific duchenne muscular dystrophy drugs market size is projected to witness a notable CAGR between 2024 and 2032, on account of the increasing collaborations among pharmaceutical companies, research institutions, and biotech firms. These partnerships, spanning clinical trials, drug development, and regulatory support, are set to enhance therapeutic options and outcomes for DMD patients in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising disease burden of DMD
    • 3.2.1.2 Increased awareness and diagnosis of DMD
    • 3.2.1.3 Growing research funding and activities
    • 3.2.1.4 Advancements in genetic research
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Patent analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Exon skipping drugs
• 5.3 Corticosteroids
• 5.4 Gene therapy
• 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Injectable

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 The Netherlands
  • 7.3.7 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 South Africa
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Aurobindo Pharma
• 8.2 Capricor Therapeutics, Inc.
• 8.3 Catalyst Pharmaceuticals Inc
• 8.4 EspeRare Foundation
• 8.5 FibroGen, Inc.
• 8.6 Italfarmaco S.p.A
• 8.7 NS Pharma
• 8.8 PTC Therapeutics, Inc.
• 8.9 Santhera Pharmaceuticals
• 8.10 Sarepta Therapeutics, Inc.
• 8.11 Solid Biosciences Inc.